Protara Therapeutics Successfully Prices $100 Million Offering
In an exciting development for Protara Therapeutics, Inc. (Nasdaq: TARA), the clinical-stage company has announced the pricing details of its latest public offering. This strategic move allows Protara to raise approximately $100 million, which will significantly aid in funding its innovative clinical programs, including the much-anticipated TARA-002.
Details of the Offering
Protara plans to sell 13,690,000 shares of common stock priced at $6.25 per share, along with pre-funded warrants for an additional 2,325,372 shares at a price of $6.249 each. This pricing reflects strong investor interest as the company also granted underwriters a 30-day option to purchase up to an extra 2,402,305 shares at the same public offering price.
Utilization of Funds
The proceeds from this offering are earmarked primarily for the clinical development of TARA-002, a key therapeutic project aimed at addressing critical healthcare needs in cancer and rare diseases. Furthermore, the funding will bolster Protara's capacity to explore additional clinical initiatives while also allowing for general corporate purposes and working capital needs.
Commitment from Joint Book-Runners
A group of prominent financial firms, including TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank, are acting as the joint book-running managers for the offering. Their involvement underscores the confidence in Protara's potential and the importance of this offer in the broader context of the company's growth strategy.
Regulatory Compliance and Transparency
The common stock and pre-funded warrants will be issued under an effective shelf registration statement. This mechanism ensures that the process of capital raising is streamlined and compliant with SEC regulations. Protara is committed to maintaining transparency and will file a prospectus supplement with the SEC that outlines the details of this offering.
Forward-Looking Statements to Consider
While this offering shows promise, it is essential for investors and stakeholders to be aware of certain forward-looking statements made by Protara. Statements regarding expected proceeds, usage of funds, and the potential for project developments carry inherent uncertainties. Protara's management is dedicated to providing updates as developments occur but emphasizes that actual future results may differ due to a variety of factors affecting operational capacity and market dynamics.
Contact Information for Inquiries
For further details regarding the public offering or inquiries about Protara's initiatives, interested parties can reach out to Justine O'Malley through the provided contact channels. Protara is keen to engage and communicate with its stakeholders as it navigates this exciting phase of growth.
Frequently Asked Questions
What is the purpose of Protara's $100 million offering?
The funds raised will primarily support the clinical development of TARA-002 and other clinical initiatives while also serving general corporate purposes.
Who are the joint book-running managers of the offering?
TD Cowen, Cantor, LifeSci Capital, Oppenheimer & Co., and Scotiabank are managing the offering.
How many shares and warrants are being offered?
Protara is offering 13,690,000 shares of common stock and pre-funded warrants for 2,325,372 additional shares.
What is the price per share for this offering?
The common stock is priced at $6.25 per share, with pre-funded warrants at $6.249 each.
Where can I get more information about this offering?
Detailed information and the final prospectus can be obtained through the SEC's website and from the offices of the joint book-running managers.
